Price Alert

Plus Therapeutics Inc. (PSTV)

NASDAQ: PSTV · Real-Time Price · USD

0.49

-0.02 (-3.01%)

At close: Aug 27, 2025, 3:59 PM

-3.01% (1D)

Bid	0.49
Market Cap	29.94M
Revenue (ttm)	5.32M
Net Income (ttm)	-19.03M
EPS (ttm)	-1.39
PE Ratio (ttm)	-0.36
Forward PE	-1.49
Analyst	Buy

Ask	0.51
Volume	3,777,644
Avg. Volume (20D)	32,038,998
Open	0.50
Previous Close	0.51
Day's Range	0.48 - 0.51
52-Week Range	0.16 - 2.31
Beta	0.67

About PSTV

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PSTV

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PSTV stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Plus Therapeutics Inc. is scheduled to release its earnings on Nov 13, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 weeks ago

Plus Therapeutics shares are trading lower after M... Unlock content with Pro Subscription

3 weeks ago

Plus Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.

News

3 weeks ago · zacks.com

Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates

Plus Therapeutics (PSTV) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.71 per share a year ago.

2 months ago · zacks.com

Plus (PSTV) Upgraded to Buy: Here's Why

Plus (PSTV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 months ago · zacks.com

Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates

Plus Therapeutics (PSTV) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.75 per share a year ago.